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Summary
Although fetal growth is generally considered to be
independent of pituitary growth hormone (GH), it is
possible that pituitary GH plays a modulatory role in
organ development or that a GH-like substance of non
pituitary origin may influence fetal growth through the
GH receptor. Accordingly, we have used immunohisto-
chemisty, northern blot analysis, the reverse transcrip-
tase-polymerase chain reaction and solution hybridiz-
ation to study the ontogeny of the GH receptor/binding
protein (BP) from the 12-day-old embryo (E12) to the
E18 rat fetus.
GH receptor/BP immunoreactivity was observed in all
major organ systems of the E18 rat fetus and was not
preferentially associated with any germ layer derivative.
A genera] increase in GH receptor/BP immunoreactivity
was evident from E12 to E18, with a marked increase
occurring between E16 and E18. Hemangioblastic tissue
was, however, strongly or intensely immunoreactive at
all stages of development, as was the placenta. Most
noteworthy of the other tissues expressing GH recep-
tor/BP immunoreactivity by day 18 were skeletal and
smooth muscle, chondroprogenitor cells, epithelial lin-
ing cells, neuronal ganglia, ependymal cells and the
adrenal cortex. In the placenta, the most prominent
immunoreactivity was associated with decidual cells.
Total RNA was isolated from E12 to E18 rat fetuses
and adult rat liver. Northern hybridization with a 35S-
labelled rat GH receptor cRNA probe revealed that 3.9
kb and 1.2 kb transcripts complementary to the rat GH
receptor ribopobe are present from at least E16. The
existence of GH receptor mRNA at E12 and E14 was
demonstrated by the polymerase chain reaction. Sol-
ution hybridization analysis demonstrated an exponen-
tial increase in the total embryonic GH receptor/BP
mRNA during fetal development. However even by E18
levels were only 8% those of adult liver.
In conclusion, we have demonstrated the presence and
defined the ontogeny of the GH receptor/BP in the rat
foetus from mid gestation. These results, when com-
bined with earlier studies of GH action on fetal tissues
suggest a revaluation of the role of GH in prenatal
growth.
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Introduction
Fetal growth and development is a complex process
involving both cellular proliferation and differentiation.
These processes are regulated through an interaction of
the endocrine systems of the fetus, mother and placenta
(Gluckman, 1986; Browne and Thorburn, 1989).
Unlike postnatal development, where growth is clearly
under central control through pituitary growth hor-
mone (GH) and insulin-like growth factor-1 (IGF-1)
(Daughaday, 1989), most of the available evidence does
not favour a role for pituitary GH in fetal growth and
development. For instance, anencephalic human
fetuses (Chard, 1989) and hypophysectomised fetuses
of numerous other species (Heggestard and Wells,
1965; Jost, 1966; Gluckman et al., 1981) have little or no
circulating immunoreactive GH, yet appear to grow
almost normally. In addition, fetal tissues, with the
exception of liver (Hill et al., 1988), were not thought to
possess the GH receptor. In the human fetus, GH can
be detected after 10 weeks gestation and reaches a peak
at 20-24 weeks (Chard, 1989) and, in fetal lambs,
plasma GH can reach 10-12 times postnatal levels
(Bassett et al., 1970). These high levels of fetal GH
have been regarded as of little functional significance
and the result of immaturity in secretory control
mechanisms (Gluckman et al., 1981). Nevertheless, a
number of fetal tissues have been shown to respond to
GH in vitro (Strain et al., 1987; Swenne et al., 1987;
Slootweg et al., 1986; Stracke et al., 1984) implying the
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presence of a functional GH receptor during fetal
development.
Because the role of GH in fetal growth and
maturation is poorly understood, we decided to define
the location of expression and ontogeny of the GH
receptor/BP in the fetus. In this study, we have used
immunohistochemistry to localise GH receptor/BP
expression in the E12 to E18 rat embryo and the
placenta. Northern blot analysis, reverse transcriptase-
polymerase chain reaction and solution hybridization
techniques were also used to demonstrate or quantify
the GH receptor/BP mRNA in the E12-E18 fetus.
Materials and methods
Production and characterisation of GH receptor/BP
monoclonal antibodies
Monoclonal antibodies (mAbs 1,5,7,43) to the rabbit GH
receptor were produced by application of hybridoma tech-
nology to splenic lymphocytes from mice immunised against a
human (h) GH affinity purified rabbit liver GH receptor
(Barnard et al., 1984). These antibodies recognise indepen-
dent epitopes on the extracellular portion of the receptor, do
not cross react with insulin or prolactin receptors in the
appropriate receptor assays and react specifically with GH
receptors in immunoblots (Leung et al., 1987). mAb 263
recognises a cross-species determinant with high affinity
(Barnard et al., 1985) and was prepared by immunization of
mice with purified rat GH receptor. mAb 263 is reactive
against the GH receptor of a number of species and does not
react with insulin or prolactin receptors in rabbit or rat liver.
Under certain conditions, mAb 263 precipitates rat and rabbit
GH receptor, although it can also compete for hormone
binding to subtypes of the GH receptor, as does mAb 7
(Barnard et al., 1985).
Tissue preparation for immunohistochemistry
Twelve female Sprague Dawley rats from the Herston
Medical School animal House (Herston, Qld.) which had
undergone timed matings were killed at 12,14,16 and 18 days
of gestation by CO2 asphyxiation. The uterine horns were
excised, embryos were dissected from maternal tissues and
then immersion fixed in Bouin's solution (0.9% picric acid,
9% (vol/vol) formaldehyde and 5% acetic acid) for 4 hours at
4°C. Tissues were subsequently dehydrated and processed for
wax embedding.
Immunohistochemistry
Paraffin was removed from the sections and they were
subjected to immunohistochemical staining according to
Lobie et al. (1990b). This involved (a) elimination of
endogenous hydrogen peroxidase activity with 0.5% H2C>2 in
phosphate-buffered saline (PBS, pH 7.4) for 15 minutes at
room temperature (25°C); (b) elimination of non-specific
protein binding by incubation in 10% normal sheep serum for
1 hour at room temperature; (c) incubation overnight at 4°C
with mouse anti-GH receptor monoclonal antibody (mAb 7 at
100 jig/ml, mAb 43 at 50 fig/ml and mAb 263 at 25 ^g/ml) or
anti-Brucella mAb (50 /ig/ml in PBS containing 1% bovine
serum albumin (BSA); (d) incubation with goat anti-mouse or
sheep anti-mouse biotinylated IgG (Amersham: diluted 1:100
in PBS containing 1% BSA) for 2 hours at room temperature;
(e) incubation with streptavidin horseradish peroxidase
complex (Amersham: diluted 1:100 in PBS containing 1%
BSA) for 1 hour at room temperature; (f) treatment with 0.05
mg/ml of diaminobenzidine in PBS containing 0.5% H2O2 for
3 minutes. Between each step, sections were washed 3 times
in PBS and once in PBS containing 1% BSA. All incubations
were performed in a humidified chamber. Sections were left
uncounterstained, or were counterstained in Mayers' haema-
toxylin, dehydrated and mounted. Controls included: (a)
omission of the primary antibody; (b) replacement of the anti-
GH receptor/BP mouse IgG (mAb 263 or 43) by unrelated
monoclonals (anti-Brucella abortus and mAb 7) of the same
isotope (IgGkl) and concentration and (c) preincubation (24
hours at 4°C) of mAb 263 with a 10 molar excess of a
recombinant truncated (1-238) version of the human GH
receptor before application to the section.
Recombinant human GH receptor, extracellular region (1-
238) produced in E. coli (Fuh et al., 1990) was kindly provided
by Genentech, Inc., S. San Francisco CA.
RNA extraction
Rats were killed by cervical dislocation under CO2 anaes-
thesia. 12-, 14-, 16- and 18-day-old embryos (n=8-12 per age
group), adult liver (n=3) and liver from pregnant rats (n=3)
were immediately removed and snap-frozen in liquid nitro-
gen.
Total cellular RNA was prepared by the method of Brooker
et al. (1980). Briefly, tissues were homogenized in 6 M
guanidinium HC1/0.2 M sodium acetate/l mM /3-mercapto-
ethanol (pH 5.2) followed by precipitation with two volumes
ethanol. The pellets were resuspended in 6 M guanidine
HCl/0.2 M sodium acetate/10 mM EDTA (pH 5.2) and
precipitated with 2 vols ethanol. The resultant pellets were
then resuspended in 7 M urea/10 mM Tris-HCl/0.1 mM
EDTA/0.1% (v/v) SDS, pH 8.5 and a phenol/chloroform,
chloroform/ether extraction was performed. The aqueous
layer was adjusted to 0.1 M potassium acetate and precipi-
tated by overnight incubation with ethanol. Remaining DNA
and tRNA were extracted by washing the pellets with 2 M
LiG. RNA was spun down and washed with 70% etha-
nol/30% (v/v) 0.1 M potassium acetate (pH 5), recovered by
centrifugation, dried under vacuum and resuspended in TE
buffer (10 mM Tris-HCl pH 7.6, 0.1 mM EDTA). RNA
concentration was determined by spectrophotometry at 260
nm (Sambrook et al., 1989).
Riboprobe synthesis
The GH receptor cRNA probe used for both northern
analysis and solution hybridization was a 560-bp BamHI
fragment (Mathews et al., 1989) corresponding to the signal
peptide and the first 167 amino acids of the GH receptor. The
plasmid DNA was linearised with EcoBI to allow for
transcription of antisense RNA using T3RNA polymerase
with ^S-labelled UTP as per Zeller and Rogers (1987).
Briefly, linearized DNA (1 ug) was incubated for 30 minutes
at 37°C with 4 u\ of 5x transcription buffer, 0.2 /il of 1 M
DTT, 60 U RNasin (Promega). 1 fi\ of 10 mM ATP, CTP and
GTP, 100 ^Ci 35S-UTP and 20 U T3RNA polymerase. The
DNA template was then digested with RNAase-free DNAase
(Promega) in the presence of RNasin and 20 fig carrier tRNA
for 10 minutes at 37°C. Subsequently, 1 ^11M DTT, 10 u\ 3 M
sodium acetate (pH 5.2) and H2O were added to a total
volume of 100 /il, the labelled probe was precipitated with
ethanol, centrifuged, dried and resuspended in 10 mM DTT.
Northern blot analysis
This was performed according to Selden (1987). 20 j/g of total
RNA was denatured in the presence of 50% formamide and
electrophoresed in an agarose gel with 2.2 M formaldehyde
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and lxMOPS (0.02 M N-morpholinopropane sulphonic
acid/0.05 M sodium acetate pH 7.0 with 0.001 M sodium
EDTA). RNA was transferred to Hybond-N nylon mem-
branes (Amersham) using a Vacugene apparatus (Pharmacia-
LKB) and 20xSSC (3 M NaCl, 0.3 M sodium citrate). The
membranes were baked at 80°C for 2 hours, prehybridized for
1 hour at 65°C in 50% formamide 2xSSC 1% SDS 20 mM
DTT, with denatured salmon sperm DNA, and subsequently
hybridized overnight in the prehybridization buffer following
addition of the S-labelled cRNA probe (2X106 cpm/ml).
Membranes were then washed twice with 2xSSC, 0.1% SDS,
20 mM DTT at 65°C for 15 minutes, dried and finally
autoradiographed at —80°C using Kodak AR5 film with
intensifying screens.
Polymerase chain reaction
This was performed as per Wang et al. (1989) in two phases as
follows:
(a) Reverse transcriptase - cDNA synthesis
In a final volume of 20 /il, the reaction contained 1 /ig of
cytoplasmic RNA, 1 mm of each dNTP, 20 U RNAsin, 100
pmoles of random hexamer, 50 U reverse transcriptase in 10
mm Tris-HCl, pH 8.3, 50 mM KC1, 15 mM MgCl2, 0.01%
Tween 20 and 0.01% NP40. The sample was incubated for 10
minutes at room temperature, then 30-60 minutes at 42°C.
The reaction was heated at 95°C for 5 minutes then quickly
chilled on ice and PCR components added.
(b) PCR amplification
To the 20 /J cDNA reaction mixture 80 jA containing 50
pmoles of the two primers, 1 U of AmpliTaq DNA
polymerase in 10 mM Tris-HCl, pH 8.3, 50 mM KC1, 1.5 mM
MgCl2, 0.01% Tween 20 and 0.01% NP40 were added.
The target sequence was amplified by 30 cycles of the
following thermal program: 95°C denaturation for 45 seconds,
60 seconds cooling to 45°C, annealing of primers at 45°C then
47°C for 30 seconds at each temperature, extension of the
primers at 60°C for 2 minutes.
Solution hybridizationJRNAse protection assays
To quantify GH receptor/BP mRNA, the 35S-labelled rat
cRNA probe was hybridized overnight at 70°C to RNA
samples from whole embryos (E12-E18), adult liver and liver
from pregnant rats as described previously (Mathews et al.,
1989). Briefly the incubation (volume 40 [A) contained 0.06 M
NaCl, 20 mM Tris-HCl (pH 7.5), 4 mM EDTA, 0.1% SDS, 10
mN dithiothreitol, and 25% formamide. After incubation,
RNA samples were treated with 40 /ig RNAase-A (Sigma) in
the presence of 100 /ig herring sperm DNA for 45 minutes at
37°C in a volume of 1 ml. Protected probe was precipitated by
addition of 100 jA 6 M trichloroacetic acid and incubation for
20 minutes at 4°C. Precipitates were collected on glass fibre
filters (GF/C, Whatman) and counted in a 1900 CA Packard
liquid scintillation counter. The hybridization signal obtained
with the rat GH receptor cRNA riboprobe in E12-E18
samples was expressed as percentage hybridization relative to
adult rat liver RNA. RNA concentration was standardized
based on absorbance at 260 nm (Sambrook et al., 1989).
Results
Specificity of immunohistochemical staining
Incubation of sections with 10% donkey serum, an
unrelated primary antibody (anti-Brucella) or a non-
cross-reacting rabbit GH receptor specific antibody
(mAb 7) at the same or greater concentration as the test
mAb did not produce a histochemical reaction (Figs
2B,3B). Both mAbs 263 and 43 (which recognise
independent epitopes) were intensely immunoreactive
in identical locations. Further, mAb 263 immunoreac-
tivity was abolished by preincubation with a 10 molar
excess of recombinant truncated (1-238) human GH
receptor (Fig. 1).
Localisation of the GH receptor/BP
General
The GH receptor/BP displayed surface membrane,
cytoplasmic and nuclear localisation (Fig. 2H), consist-
ent with localisation of the receptor by immunogold
electron microscopy in the adult to the rough endoplas-
mic reticulum, cytoplasm, nuclear membranes, hetero-
chromatin and nucleolus (Lobie et al., 1991). Weak
immunoreactivity was detected in the E12 embryo, and
a general increase of GH receptor/BP immunoreactivity
was observed from E12 to E18, with a marked increase
occurring between E16 and E18. Further description of
the GH receptor/BP distribution will be based on the
E18 embryo. For comparison of immunoreactivity
between E12 and E18 the following terms will be used;
intense (4+), strong (3+), moderate (2+) and weak
()
Embryonic ectoderm
General body ectoderm
The cutaneous epidermal cells and their derivatives, the
respiratory nasal epithelium, the epithelia lining the
labia, cheeks, gingiva and palates and their respective
duct-lining cells, the epithelia of the cornea and
conjunctiva, secretory and duct lining cells of the
lacrimal gland, the embryonic enamel organ and
ameloblasts, and the epithelium of the lower anal canal
of the E18 embryo were strongly to intensely immuno-
reactive (Fig. 1). The analogous structures in the E16
embryo were weakly immunoreactive and in E14 and
E12 were immunonegative.
Neural plate ectoderm
The neurones of the central nervous system, (telen-
cephalon, diencephalon, metencephalon and myelen-
chephlon) and spinal cord, of macroglial cells and
ependymal cells were all immunoreactive (Fig. 2G). In
the E18 embryo, the ependymal cells were intensely
immunoreactive (especially those of the choroid plexus)
followed by neurones (strong), whereas the developing
fibre tracts were only moderately immunoreactive. All
retinal cells of the E18 embryo derived from neural
plate ectoderm were strongly immunoreactive. In the
E16 embryo, weak to moderate immunoreactivity was
observed in neurones of the central nervous system and
spinal chord, with the exception of the medullary plate,
which was moderately immunoreactive. The E16 epen-
dymal cells of the choroid plexi and ventricular lining
were strongly immunoreactive. Derivatives of the
neural plate ectoderm in E14 and E12 embryos were
weakly immunoreactive or negative.
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Neural crest ectoderm
The neurones of the dorsal root and cranial ganglia
were intensely immunoreactive in the E18 fetus (Fig.
2H). These were strongly immunoreactive in E16 and
weak to moderately immunoreactive in E14 and E12.
Schwann (ANS) cells, dentine-producing osteoblasts of
the tooth germs and osteogenic elements of the cranium
were all strongly immunoreactive whereas chromaffin
cells of the adrenal medulla were weakly stained or
immunonegative.
Ectodermal placodes
The receptor and sustentacular cells of the E18
olfactory epithelium were strongly immunoreactive,
E16 moderately immunoreactive and E14 and E12
weakly immunoreactive. The epithelial walls of the E18
inner ear were intensely immunoreactive (Fig. 2). The
developing lens fibres and the superficial epithelium of
the lens were strong to intensely immunoreactive.
Rathke's pouch and the adenohypophysis was moder-
ately immunoreactive in the E18 embryo.
Embryonic mesoderm
Paraxial mesoderm
The developing striated musculature of the trunk (as
well as limb muscles and lingual muscles that develop in
situ) was intensely immunoreactive by E18 (Figs 1A,
2B), strongly immunoreactive (E16) or weakly immu-
noreactive (E14,E12). The chondroprogenitor cells of
the vertebrae and other skeletal components (inverte-
bral disks, ribs, costal cartilages) were intensely
immunoreactive, whereas chondrocytes of the same
structures displayed heterogeneous immunoreactivity
from strong to negative at E18 (Fig. 2K). The analogous
structures of younger embryos were essentially immu-
nonegative.
Intermediate mesoderm
The renal capsules and nephric tubules were strongly
immunoreactive in the E18 embryo. Epithelial com-
ponents of the mesonephric (Wolffian) duct, ureter,
collecting tubules, epididymis, vas deferens, seminal
vesicles and paramesonephric (Mullerian) ducts (uter-
us) were immunoreactive. Gbnadal tissues were
strongly immunoreactive and cells of the adrenal cortex
and mesothelium were intensely immunoreactive. The
analogous structures of younger embryos followed the
general age-dependent increments.
Lateral plate mesoderm
The lateral plate mesoderm becomes separated into the
somatic and splanchnic layers. Mesenchymal conden-
sations transform the somatopleuric mesenchyme into
the osseous, cartilaginous, muscular, vascular, lympha-
tic and connective tissue of the body wall (Fig. 2).
Vascular elements (endothelium and haemopoietic
cells) were intensely immunoreactive at all stages of
development (E12-E18) in contrast to the weak or
immunonegative non-haemangioblastic tissues of E12
and E14. E18 myoblasts were intensely immunoreactive
(Fig. 2J) and fibroblasts and osteo and chondro
progenitor cells were strongly immunoreactive whereas
chondrocytes displayed heterogeneous immunoreac-
tivity (Fig. 2G) (immunoreactivity, when present, was
mainly associated with hypertrophic chondrocytes).
The splanchopleuric mesenchyme clothes the endoder-
mal gut tube (Fig. 2C), its subdivisions and glandular
derivatives and the walls of the tracheobronchial tree
(Fig. 2D) and the urinary bladder. Non-striated muscle
and vascular derivatives of these structures were
intensely immunoreactive (E18), as were fibroblasts.
Embryonic endoderm
All derivatives of the embryonic endoderm (salivary
glands, glandular and duct lining epithelia of the
esophagus, stomach, small intestine, colon, hepato-
cytes, pancreatic acinar and duct-lining cells, pharyn-
geal epithelium, tracheobronchial alveolar respiratory
tree, transitional epithelium lining the urinary bladder,
parenchyma of prostate) of the E18 embryo were
intensely or strongly immunoreactive (Fig. 1A). The
analogous structures of the E12 to E16 embryos
displayed weak (E12, E14) to moderate (E16) immuno-
reactivity.
Placenta
Decidual cells of the E12 placenta were strongly
immunoreactive (E12) and a slight gradation in inten-
sity was observed to E18, where they were intensely
immunoreactive. Trophoblastic cells and epithelial cells
of the amniotic membrane were weak and moderately
immunoreactive respectively at E12 and similarly
progressed to display strong immunoreactivity at E18.
Northern blot analysis
Northern blots of the embryonic RNA hybridized with
the rat GH receptor 35S-cRNA probe revealed 3.9 and a
1.2 kb transcripts, coding for the full-length receptor
and the putative BP respectively (Smith et al., 1989;
Baumbach et al., 1989) (Fig. 4). In addition, variable
times of exposure of X-ray film to the hybridized
membranes (overnight, 3 days, 3 weeks) revealed a
graded intensity of hybridization from E14 to E18, adult
liver and liver from pregnant rats (Fig. 4A).
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
Since GH receptor mRNA was not readily detectable at
E12 and E14 by conventional northern blot analysis,
RT-PCR was used to demonstrate GH receptor gene
expression during this period. The scheme of the
experiment with the predicted size of the amplified
cytoplasmic fragment is shown in Fig. 5. GH receptor
mRNA is unequivocally present at E12 and E14 (Fig.
5).
Solution hybridization
Solution hybridization (nuclease protection assay) was
used to quantify the changes in GH receptor/BP mRNA
from E12 to E18 in whole embryos. As seen in Fig. 6,
BFig. 1. Low-power photomicrograph of the E18 embryo.
Magnification bar is 1000 /Jin. Both sections have been
counterstained with haematoxylin to show nuclei. (A) mAb
263 immunoreactivity in the E18 rat fetus. Note that the
immunoreactivity is associated with many organ systems.
(B) Adjacent section to that of Fig. 1A when mAb 263 was
preincubated (24 hours at 4°C) with a recombinant soluble
form of the human GH receptor (1-238) before application
to the section.
Fig. 3. (A) GH receptor/BP immunoreactivity (mAb 263)
in the decidual cells of the placenta at 14 days gestation.
(B) Adjacent control section (mAb 7) showing lack of
immunoreactivity. The magnification bar is 100 //m. B
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Fig. 2. GH receptor/BP immunoreactivity in the rat
embryo/fetus. Magnification bar is 100 fan. (A) mAb 263
immunoreactivity in the E18 liver. (B) mAb 43
immunoreactivity in the developing submandibular gland of
an E18 embryo (d=duct, e=epithelial component). (C) mAb
263 immunoreactivity in the midgut of the E18 embryo. Note
the prominent immunoreactivity associated with the epithelial
(e) and smooth muscular (m) components (1=lumen). (D)
mAb 263 immunoreactivity in the lung of an E18 embryo.
Note the prominent immunoreactivity associated with the
epithelial (e) and smooth muscular (arrow) components of
the developing bronchioles. (E) mAb 263 immunoreactivity
in the E14 embryo. Note the prominent immunoreactivity in
the haemopoietic cells (h) and vascular endothelial lining
(arrow), and the weak immunoreactivity of the surrounding
mesenchymal (m) and epithelial (e) tissue. (F) mAb 263
immunoreactivity in the E18 epidermis (e) and the
developing hair follicle (f). Note also the prominent nuclear
immunoreactivity present in some cells (d=dermis). (G)
mAb 43 immunoreactivity in the developing semicircular
canals of the inner ear. Note the intense epithelial (e)
immunoreactivity and the moderate immunoreactivity in the
underlying mesenchyme. Note also the heterogeneous
immunoreactivity present in chondrocytes (c) (1=lumen). (H)
mAb 43 immunoreactivity in the metencephalon of the E18
embryo. (I) mAb 263 immunoreactivity in the trigeminal
ganglion (g) of the E18 embryo. Note the intense
immunoreactivity associated with the ganglionic neurones. (J)
mAb 263 immunoreactivity in myoblasts of the E18 embryo.
(K) Lack of immunoreactivity in the E18 muscle with mAb 7
in the adjacent section to that of Fig. 2J. (L) mAb 263
immunoreactivity in the E18 epiphysial region of the femur
bone. Note the absence of immunoreactivity on most of the
hypertrophic chondrocytes (h) and heterogenous staining of
the stem (s) and proliferative (p) zone. Note also the
prominent immunoreactivity of the myotubules on both sides.
3.9 kb-
1.2 kb-
Fig. 4. Northern blot analysis of E12-E18 rat embryo and
adult rat liver RNA with a rat GH receptor riboprobe (as
described in Materials and methods). With a 35S-labelled
riboprobe the 3.9 and 1.2 kb transcripts are present from
at least E16 (3 days exposure) and become more obvious
with prolonged exposure (lane 1=liver from pregnant rat;
2=adult liver; 3=E18; 4=E16; 5=E14; 6=E12).
GH receptor/BP mRNA concentration, (expressed as a
percentage of adult liver RNA) increased exponentially
from E12 to E18.
GHR.L: 5' OAQ GAS GTG AAC AAC ATC TTG GGC 3'
GBR.R: 3' ACC ACC TOC TOG TGT AAT GTC 3'
B
GHR.L
GH Receptor [_
GHR.R
-75
Fig. 5. (A) primer sequences. (B) Diagrammatic
representation of the amplified insert taken from position
961 bp to 1478 bp in the intracellular region of the rat GH
receptor (Baumbach et al., 1989). (C) The photograph
shows the amplified fragment for the different age groups
flanked by molecular weight markers as follows: 1.
Molecular weight markers (Hinfl digest of pBR.322). 2.
E18. 3. E14. 4. E12. 5. Molecular weight markers (£coRI
and Hindm digest of ADNA).
Discussion
We have demonstrated a widespread distribution of the
GH receptor/BP in the rat embryo, analogous to the
adult (Barnard et al., 1988; Mathews et al., 1989; Lobie
et al., 1990a-c; Waters et al., 1990) where GH has
actions on many postnatal tissues (Isaksson et al.,
1985). In the fetus the most prominent immunoreac-
tivity was associated with epithelial and endothelial cell
types, and with myoblasts, ganglion cells and haeman-
gioblastic tissues. In support of these findings, in vitro
responses of several fetal tissues to GH have been
reported. These responses include; proliferation of 12-
16 week fetal human hepatocytes in response to human
GH (Strain et al., 1987), proliferation of day 18 fetal
mouse osteoblasts (Slootweg et al., 1988), increased
IGF-I and alkaline phosphatase secretion from day 18
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Fig. 6. Ontogeny of GH receptor mRNA during
embryogenesis as determined by solution hybridization
assay. The GH receptor/BP mRNA concentration is
expressed as a percentage of adult rat liver mRNA
hybridization to the rat GH receptor/BP cRNA probe
where adult liver RNA gave 2060 cpm/^g RNA±274.
Solution hybridization was performed as described in
materials and methods. **P<0.01 between E12 and E14.
***P<0.001 between E16,18 and E12.14.
rat tibia (Stracke et al., 1984), increased /S-islet cell
proliferation in fetal rat islets (Dudek et al., 1984),
elevated insulin release in human islet cell cultures
(Sandier et al., 1987) and increased myelin synthesis in
fetal rat brain cultures (Almazan et al., 1985).
Comparatively low levels of GH receptor/BP mRNA
were detected throughout embryogenesis. However,
even very low levels of GH receptor are able to mediate
GH effects; for example, adult rat tibial growth plate
chondrocytes possess only 5% of the GH receptor of
hepatocytes yet respond to GH with enhanced IGF-I
mRNA synthesis (Isgaard et al., 1988) and RIN5
pancreatic cells (Billestrup and Martin, 1985) express
less than 5% of the receptor number of rat hepatocytes
(Ranke et al., 1976) or adipocytes (Fagin et al., 1980)
but are able to respond to GH.
Classical decapitation and hypophysectomy exper-
iments have generally found that pituitary GH contrib-
utes less than 20% to fetal growth (see Gluckman,
1986). Therefore placental lactogen has been proposed
as a growth hormone able to substitute for pituitary GH
(Daughaday et al., 1979). However, in receptor assays,
purified rat placental lactogen is not somatogenic
(Robertson and Friesen, 1975). It is possible that a
placental growth hormone (Ogilvie et al., 1990) is
responsible for fetal growth. This hormone could be
analogous to the human placental GH variant of
Frankenne et al. (1988), but present in fetal plasma. In
preliminary experiments, we have found quite high
levels of GH-like activity (>400 ng/ml) in E17 fetal
plasma using a homologous rat radioreceptor assay. We
propose that such a factor would act via the fetal GH
receptor/BP before pituitary GH appears on E19
(Strasser and Mialhe, 1975).
Since both long and short forms of the GH receptor
mRNA are present in the fetus, it seems likely that full-
length receptor (Leung et al., 1987) and binding protein
(Smith et al., 1989; Baumbach et al., 1989) are present.
Ymer and Herington (1990) have recently reported
short and long transcripts in fetal rabbit liver, skeletal
muscle, heart, kidney and lung. It is intriguing to
speculate on the role of the BP in a milieu lacking
pituitary GH (E18), particularly in the light of our
demonstration that the GH BP is present in the nucleus
(Lobie et al., 1991). The role of the BP may be to
interact with a placental GH to mediate its actions
during embryogenesis. Since the circulating level of GH
BP is low at birth (Daughaday et al., 1987) it would
seem likely that any modulatory action would occur at
the tissue level.
The increment in GH receptor/BP immunoreactivity
and mRNA observed from E12 to E18 suggests that
GH-like effects on prenatal development, are likely to
occur during the later fetal period, coinciding with a
state of maximal organogenesis. This suggests a differ-
entiative as well as proliferative role for GH during fetal
morphogenesis. Such a proposal is supported by the
lack of villar development of fetal small intestinal
transplants in hypophysectomised hosts, and sub-
sequent normal villar morphogenesis following GH
replacement therapy (Cooke et al., 1986). GH is also
necessary for normal differentiation of fetal paw
transplants in hypophysectomised hosts (Cooke et al.,
1983).
The role of the fetal rat GH receptor/BP would be
best addressed with a receptor-deficient mutant. Such a
condition exists in the Laron dwarf (Godowski et al.,
1989), and most newborn Laron dwarfs are greater than
2 standard deviations shorter than normal (Laron et al.,
1971). This finding is consistent with the ovine hypophy-
sectomy studies of Mesiano et al. (1987), and supports a
role for GH in fetal skeletal growth. It is relevant that
we found intense GH receptor immunoreactivity in
skeletal chondroprogenitor cells and osteoblasts in
bone undergoing intramembranous ossification, in
agreement with previously mentioned in vitro studies
on murine fetal bone cells (Slootweg et al., 1988) and
our studies on the postnatal ontogeny of the GH
receptor in the tibial growth plate (Barnard et al., 1988)
Intense GH receptor/BP immunoreactivity was seen
in hemangioblastic tissue of the day 12 embryo before
any other organ system exhibits prominent receptor/BP
reactivity. It may be relevant that the circulatory system
is the first to become functional during intrauterine
development and the first to exhibit strong GH receptor
expression. Golde et al. (1978) demonstrated that
GH receptor/binding protein during embryogenesis 875
nanogram concentrations of GH stimulate erythropoi-
esis of human erythroblasts, and GH is known to
modulate lymphocyte function postnatally (Kiess,
1983). Intense immunoreactivity of E18 endothelial
cells lining blood vessels in all embryonic tissues is
consistent with observations (Hausman, 1989) that the
number of small capillaries in muscle sections from
decapitated or hypophysectomized pigs is reduced
compared with muscle from control fetuses, as is the
capillary/fibre ratio.
Prominent immunoreactivity was observed in both
skeletal and smooth muscle precusors in our study. This
finding is supported by a recent report that GH receptor
mRNA is present in fetal rabbit muscle (Ymer and
Herington, 1990). Mathews et al. (1989) also observed
substantial levels of GH receptor/BP mRNA in post-
natal skeletal muscle. Although it has been difficult to
show an in vitro effect of GH on myoblast replication,
Isgaard et al. (1989) have reported that pulsatile GH
administration markedly increases IGF-I mRNA in
skeletal muscle. During myogenic differentiation, the
levels of IGF-I increase by 6-10 fold within 48-72 hours
concurrent with an increase in IGF-I receptor and
binding protein (Tolleffsen, 1989).
Our localisation of GH receptor/BP to nervous tissue
beginning with the neuroepithelium is in accord with a
considerable body of data supporting the concept of a
GH axis in the brain, and forms the subject of a
separate study (Lobie et al., 1989).
The distribution of fetal IGF-I immunoreactivity
observed by Hill et al. (1989) is very similar to the GH
receptor immunoreactivity that we report here. It is of
interest that rat fetal IGF-I mRNA levels are higher
than adult levels in all tissues examined (intestine, lung,
brain) except for the liver (Lund et al., 1986) and that
fetal IGF-I mRNA rises from day 11 (Rotwein et al.,
1987), when GH receptor immunoreactivity and
mRNA are first detected. IGF-II mRNA, on the other
hand, appears somewhat earlier in fetal development
and does not correlate temporally with GH receptor
expression, although spatially there are many simi-
larities (Beck et al., 1987; Stylianopoulou et al., 1988).
The observation that GH receptor/BP immunoreac-
tivity is widely distributed in the placenta in both fetal
and maternal compartments suggests that the GH
receptor/BP may play an integrated role in fetal
development both directly at the fetus and indirectly at
the placental/nutrient supply level. Ymer et al. (1989)
recently reported GH binding protein at high levels in
both maternal and fetal compartments of rabbit
placenta, with short and full-length GH receptor
mRNA being present in the fetal placenta. These
authors suggested that GH may play a role in placental
metabolism. Alternatively the placental GH recep-
tor/BP could mediate GH-dependent IGF-I synthesis as
the human placenta is capable of synthesis of IGF-I
(Mills et al., 1986).
In conclusion, we have demonstrated the presence of
the GH receptor in the rat embryo/fetus with maximum
expression of the receptor during organogenesis. The
results presented here provide a basis for understanding
the role of GH or GH-like hormones in fetal growth
and development.
This work was supported by a grant from the National
Health and Medical Research Council of Australia.
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